Metastatic spinal cord compression (MSCC) occurs when the spinal cord or cauda equina is compressed by vertebral collapse or tumour growth, leading to potential loss of neurological function and requiring urgent oncological intervention.

Early recognition, rapid referral, and timely management within 24 hours are critical to preserving spinal function. Treatment options include radiotherapy, systemic anti-cancer therapy (SACT) such as chemotherapy, immunotherapy, or hormone therapy, surgery and orthosis, all aimed at preventing neurological deterioration and relieving symptoms.

Many patients suspected of MSCC have spinal metastases without cord compromise or non-malignant degenerative spinal conditions; collaborative care between MSCC and other specialist services is often necessary, especially in patients with multiple comorbidities. Increasingly, patients may show radiological signs of impending MSCC but have no neurological issues or instability; swift clinical assessment is essential to guide treatment        decisions and avoid delays.

Follow this link to the pathway document

This pathway has been developed to support best practice in the Same Day Emergency Care (SDEC) management of cancer patients presenting with suspected spinal metastases and MSCC . It summarises current evidence and expert consensus to inform local service development and delivery. This document is provided as a template for adaptation by individual organisations. It should be reviewed, amended where necessary, and formally approved through the organisation’s clinical governance and risk management processes prior to implementation.

Clinical decisions must always be based on the professional judgment of the responsible healthcare practitioner, taking into account the specific circumstances, preferences, and needs of each patient, as well as local service arrangements and policies.

The UKAOS Expert Advisory Group has exercised reasonable care in preparing this document; however, it accepts no liability for the use, adaptation, or implementation of the pathway by third parties. Responsibility for clinical governance, local approval, and safe implementation rests with the adopting organisation.